Jüke Systemtechnik GmbH is pleased to announce that it has entered into a long-term strategic partnership with evorion biotechnologies GmbH. Heinrich Jürgens, the managing partner of Jüke, points out the importance of the strategic partnership and says “We are excited to be a new partner and shareholder of evorion biotechnologies. We envision this investment as a great strategic partnership as both the companies can deeply benefit from each other’s expertise in their respective markets.”
evorion specializes in the field of live-cell analytics. The company has developed a new innovative system “CellCity” that enables functional phenomics at single-cell resolution. The unique microfluidic chip-based platform allows researchers to investigate many complex biological questions such as cellular interactions via long-term live-cell analysis in a 3D microenvironment, which was not possible before due to technological limitations. evorion’s product family covers two areas: technological instruments for cell analysis and the microfluidic array chips which has many applications for a range of research areas, like cell therapy, immunology, infectious diseases, and cancer. “We have closed our financing round with a group of new and existing investors, and are very delighted to welcome Jüke as a new shareholder. Jüke has a very long track record in engineering, production and regulatory affairs management, we are confident that their expertise will play a great role in expanding commercialization of our CellCity System worldwide at industry standards” said Dr. Sebastian Bühren, CEO & Co-founder of evorion biotechnologies. “As a long-term collaboration partner, Jüke will also be actively involved in further developments and optimization of our next-generation products” he added.
Jüke is an experienced service provider and has extensive expertise in developing and producing high-precision devices for companies in the fields of medical technology, analytical, bio- and laboratory technology and photonics. Jüke’s experts have many years of know-how with complex mechatronic assemblies and devices, programming and software, system integration and industry standard-compliant documentation.
In this long-term strategic partnership Jüke is assuming the production of the CellCity instruments and will establish the supply chain and quality management. While evorion will focus on the strategies for the commercialization of the CellCity system and innovate further based on customers and market needs. “Together with evorion, we are looking forward to expanding into highly attractive markets with various ground-breaking applications in biomedical, translational and clinical research,” emphasizes Martin Hovestadt, managing partner of Jüke.
